#Tokyo #Regenesome #Retinol #Bycel Technology

Joint Patent Application: Regenesome and Tokyo University

A groundbreaking collaboration between Regenesome Inc., a subsidiary of Space Seed Holdings based in Tokyo, and Dr. Noriyuki Uchida from the Tokyo University of Agriculture and Technology has led to a joint patent application focusing on a novel Bycel formulation. This formulation is designed to maintain the stability of retinoids, a category of compounds that includes retinol, a crucial vitamin A derivative. The patent application, numbered 2026-084416, was filed on May 19, 2026.

The Importance of Retinol and Its Challenges

Retinol has long been recognized for its effectiveness in the healthcare sector, making it an essential ingredient in many skincare products. Its benefits include promoting cell turnover and improving skin texture; however, it faces significant challenges. One of the primary hurdles in utilizing retinol in products is its sensitivity to environmental factors such as air and light, which can lead to degradation. Additionally, manufacturers must consider consumer experience, ensuring that products are gentle on the skin while delivering effective results. Therefore, the demand for innovative delivery systems that can stabilize and effectively convey this ingredient is paramount.

Understanding Bycel Technology

Bycel technology represents a cutting-edge solution in nano-sized delivery systems. It enables the encapsulation of active ingredients within a carrier, allowing for stable retention even under challenging conditions. The research conducted by Regenesome has focused specifically on developing a Bycel formulation that can securely house retinoids, thereby opening new avenues for their application in various products. The efforts culminated in the recent patent filing, reflecting the commitment to harnessing this technology for practical use.

Overview of the Patent Application

Future Developments

This patent application serves as a pivotal step for Regenesome as it seeks to advance the commercialization of healthcare products. The ultimate goal is to ensure that beneficial ingredients, such as retinol, are delivered effectively and safely to consumers. While specifics regarding product timelines and specifications are still in the development phase, Regenesome is committed to keeping stakeholders informed as the project progresses.

About Regenesome Inc.

Regenesome focuses on employing nanoparticles to provide innovative solutions targeting aging suppression and regenerative medicine. The company has established its headquarters and research facility, the Takanawa Longevity Lab, in Takanawa Gateway City. It operates under the brand name